Actively Recruiting
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-09-22
50
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Treatment of Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis (LCH) Using a Low-Dose Cytarabine Combined with Thalidomide Regimen.
CONDITIONS
Official Title
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clearly diagnose and treat adult patients with multisystem or single-system multifocal LCH
- Aged between 18 and 70 years
- Multisystem involvement or single-system multifocal disease
- No prior systemic treatment (patients who have only received local radiotherapy or surgery may be enrolled)
- ECOG performance status score �3 2
- Judged by clinicians as suitable for treatment with this protocol
- Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent
You will not qualify if you...
- Patients with LCH involving the central nervous system
- Single-system single-lesion LCH
- Subjects who have undergone major surgery within 4 weeks prior to the first dose in the study
- Subjects who have received radiotherapy within 4 weeks prior to the first dose in the study
- Subjects with a history of myocardial infarction within the past year
- Patients with New York Heart Association (NYHA) class 3 or 4 congestive heart failure, or a history of NYHA class 3 or 4 congestive heart failure
- Pregnant or lactating women
- Abnormal liver and kidney function: creatinine level �3176.8bcmo/l (2mg/dl), transaminase and bilirubin levels more than 2 times the upper limit of normal (for LCH patients with liver involvement, bilirubin levels more than 10 times the upper limit of normal)
- Abnormal blood counts: absolute neutrophil count less than 1�310^9/L, platelet count less than 50�310^9/L
- Patients or their families unable to understand the conditions and objectives of this study
- Any other circumstances in which the investigator deems the patient unsuitable to participate in this trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
Actively Recruiting
Research Team
X
Xinxin XX Cao, doctor
CONTACT
H
Huilei HL Miao, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here